drugset / Trial / NCT02308072
Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer
Phase 1
Completed
16 enrolled
University College, London
AstraZeneca · collabCancer Research UK · collab
NaSingle-groupOpen-labelTreatment
Summary
The phase I trial aims to determine the recommended phase II dose (RP2D) and schedule of olaparib in combination with standard cisplatin-based chemoradiotherapy, in patients with high-risk locally advanced squamous cell carcinoma of the head and neck (HNSCC), by assessing the safety and tolerability of the treatment combination.
Timeline
- Start
- 2015-09
- Primary completion
- 2020-06
- Completion
- 2026-04-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaparib | Small molecule | 50 mg | — |
| Subject | Olaparib | Small molecule | 100 mg | — |
| Subject | Olaparib | Small molecule | 150 mg | — |
| Subject | Olaparib | Small molecule | 200 mg | — |
| Background | Cisplatin | Other / unclassified | 35 mg/m2 | Intravenous |